Antiplatelet Therapies in Intercyber Hemorrhage - Is There a Paradigm Shift?

I think the antiplatelet therapies in ICH is currently in that realm of safety, and there's emerging data also in this issue of stroke looking at that aspirin use. So we have to keep our eyes on these incoming trials that are basically targeting IL-1 receptors and antagonizing these receptors. How do you think the future treatment of ICH and sub-rattent hemorrhage will look like, say, 20 years from today?